company background image
SOLT.F logo

Sosei Group OTCPK:SOLT.F Stock Report

Last Price

US$10.53

Market Cap

US$946.8m

7D

0%

1Y

-37.2%

Updated

27 Mar, 2024

Data

Company Financials +

Sosei Group Corporation

OTCPK:SOLT.F Stock Report

Market Cap: US$946.8m

SOLT.F Stock Overview

Sosei Group Corporation develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom.

SOLT.F fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Sosei Group Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Sosei Group
Historical stock prices
Current Share PriceJP¥10.53
52 Week HighJP¥22.78
52 Week LowJP¥8.56
Beta0.55
1 Month Change20.71%
3 Month Change7.63%
1 Year Change-37.20%
3 Year Change-36.40%
5 Year Change-6.77%
Change since IPO-75.66%

Recent News & Updates

Recent updates

Shareholder Returns

SOLT.FUS PharmaceuticalsUS Market
7D0%1.2%0.4%
1Y-37.2%25.8%28.8%

Return vs Industry: SOLT.F underperformed the US Pharmaceuticals industry which returned 23.9% over the past year.

Return vs Market: SOLT.F underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is SOLT.F's price volatile compared to industry and market?
SOLT.F volatility
SOLT.F Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: SOLT.F's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine SOLT.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1990350Chris Cargillhttps://soseiheptares.com

Sosei Group Corporation develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company’s development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders.

Sosei Group Corporation Fundamentals Summary

How do Sosei Group's earnings and revenue compare to its market cap?
SOLT.F fundamental statistics
Market capUS$946.77m
Earnings (TTM)-US$47.53m
Revenue (TTM)US$84.35m

11.2x

P/S Ratio

-19.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SOLT.F income statement (TTM)
RevenueJP¥12.77b
Cost of RevenueJP¥1.29b
Gross ProfitJP¥11.48b
Other ExpensesJP¥18.67b
Earnings-JP¥7.19b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 09, 2024

Earnings per share (EPS)-80.42
Gross Margin89.90%
Net Profit Margin-56.35%
Debt/Equity Ratio103.5%

How did SOLT.F perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.